Drug:
Reaction: DISEASE PROGRESSION
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26555620 |
GB |
||
Disease progression, |
||||
DOXORUBICIN, PREDNISONE, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 2 | 26555660 |
TR |
70 | 1 |
Cough, Hypothyroidism, Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 3 | 26555984 |
US |
||
Disease progression, |
||||
EDARAVONE, EDARAVONE, |
||||
| 4 | 26556239 |
EU |
70 | |
Disease progression, Asthenia, Constipation, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 5 | 26556240 |
EU |
||
Disease progression, Alopecia, Asthenia, Diarrhoea, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 6 | 26556259 |
EU |
||
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 7 | 26556696 |
US |
38 | 1 |
Disease progression, |
||||
SULFAMETHOXAZOLE AND TRIMETHOPRIM, IMATINIB, METHYLPREDNISOLONE, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM, PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, |
||||
| 8 | 26557700 |
CN |
70 | 1 |
Disease progression, |
||||
AMLODIPINE, DONEPEZIL HYDROCHLORIDE, |
||||
| 9 | 26557916 |
EU |
66 | 2 |
Death, Breast cancer, Malignant neoplasm progression, Lung disorder, Metastases to bone, Pleural effusion, Pleural disorder, Disease progression, Computerised tomogram abnormal, |
||||
RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 10 | 26557989 |
JP |
78 | 2 |
Anaemia, Disease progression, |
||||
DURVALUMAB, DURVALUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 11 | 26558325 |
CN |
62 | 1 |
Diplopia, Dysuria, Hypoaesthesia, Disease progression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, DOXORUBICIN, |
||||
| 12 | 26558426 |
US |
88 | 2 |
Disease progression, Device delivery system issue, Product dose omission issue, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 13 | 26558892 |
IN |
26 | 1 |
Drug ineffective, Disease progression, Product prescribing issue, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, CARBOPLATIN, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, BEVACIZUMAB, |
||||
| 14 | 26558905 |
JP |
7 | 2 |
Disease progression, |
||||
ZONGERTINIB, |
||||
| 15 | 26559064 |
EU |
37 | |
Disease progression, Therapy partial responder, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 16 | 26559633 |
CN |
70 | 2 |
Disease progression, Myelosuppression, Pneumonia, Aspergillus infection, Influenza, |
||||
DOXORUBICIN, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, |
||||
| 17 | 26560225 |
69 | ||
Metabolic dysfunction-associated steatohepatitis, Disease progression, |
||||
RESMETIROM, DEXLANSOPRAZOLE, TIOTROPIUM BROMIDE AND OLODATEROL, SPIRONOLACTONE, FAMOTIDINE, EZETIMIBE, MELOXICAM, ENALAPRILAT, TAMSULOSIN HYDROCHLORIDE, GABAPENTIN, TIZANIDINE HYDROCHLORIDE, CARVEDILOL, BENAZEPRIL HYDROCHLORIDE, |
||||
| 18 | 26560500 |
JP |
48 | 1 |
Disease progression, Rhabdomyolysis, Drug ineffective, |
||||
DOXORUBICIN, TRABECTEDIN, PAZOPANIB, PAZOPANIB HYDROCHLORIDE, |
||||
| 19 | 26565973 |
78 | 2 | |
Disease progression, Insomnia, Rash, Neutropenia, Fatigue, Urticaria, |
||||
POMALIDOMIDE, LENALIDOMIDE, |
||||
| 20 | 26550211 |
US |
||
Disease progression, Off label use, |
||||
TECLISTAMAB-CQYV, |
||||
| 21 | 26550362 |
US |
1 | |
Disease progression, |
||||
FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, OXALIPLATIN, |
||||
| 22 | 26550793 |
JP |
7 | 1 |
Hepatic function abnormal, Cytomegalovirus enteritis, Disease progression, Off label use, |
||||
RITUXIMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 23 | 26550973 |
EU |
47 | 2 |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, ERLOTINIB HYDROCHLORIDE, ERLOTINIB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 24 | 26551059 |
EU |
70 | 1 |
Respiratory failure, Diarrhoea, Weight decreased, Disease progression, |
||||
NINTEDANIB, NINTEDANIB, |
||||
| 25 | 26551123 |
AU |
53 | 1 |
Disease progression, |
||||
ATEZOLIZUMAB, CARBOPLATIN, ETOPOSIDE, |
||||
| 26 | 26551544 |
US |
1 | |
Disease progression, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 27 | 26551608 |
SG |
79 | 2 |
Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, |
||||
| 28 | 26552083 |
CN |
||
Disease progression, |
||||
DEGARELIX, |
||||
| 29 | 26552131 |
EU |
1 | |
Disease progression, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 30 | 26552292 |
EU |
43 | 1 |
Multiple acyl-coenzyme A dehydrogenase deficiency, Disease progression, |
||||
SERTRALINE, |
||||
| 31 | 26553399 |
US |
||
Disease progression, Off label use, |
||||
TECLISTAMAB-CQYV, DARATUMUMAB, POMALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 32 | 26554510 |
PK |
44 | 2 |
Disease progression, Neoplasm malignant, |
||||
ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, |
||||
| 33 | 26554703 |
EU |
46 | 1 |
Drug ineffective, Disease progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 34 | 26554874 |
AU |
80 | 1 |
Disease progression, Immune-mediated enterocolitis, |
||||
ATEZOLIZUMAB, CARBOPLATIN, ETOPOSIDE, |
||||
| 35 | 26555061 |
EU |
||
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 36 | 26555067 |
GB |
||
Disease progression, Alopecia, Abdominal discomfort, Decreased appetite, Sensitive skin, Madarosis, Nausea, Fatigue, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 37 | 26555106 |
US |
49 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 38 | 26557651 |
84 | 1 | |
Dementia Alzheimer^s type, Disease progression, Hypophagia, Decubitus ulcer, Impaired healing, |
||||
BREXPIPRAZOLE, DONEPEZIL HYDROCHLORIDE, MEMANTINE, MEMANTINE HYDROCHLORIDE, QUETIAPINE, |
||||
| 39 | 26565479 |
82 | 1 | |
Disease progression, |
||||
PIRFENIDONE, |
||||
| 40 | 26547821 |
AU |
59 | 2 |
Disease progression, |
||||
ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, |
||||
| 41 | 26548151 |
2 | ||
Disease progression, |
||||
PEXIDARTINIB HYDROCHLORIDE, |
||||
| 42 | 26542000 |
GB |
1 | |
Disease progression, Renal failure, Light chain analysis increased, |
||||
TALQUETAMAB, |
||||
| 43 | 26542292 |
US |
52 | 1 |
Disease progression, |
||||
LENALIDOMIDE, |
||||
| 44 | 26542573 |
EU |
2 | |
Chronic kidney disease, Disease progression, Drug ineffective, |
||||
PEGCETACOPLAN, |
||||
| 45 | 26542708 |
CN |
60 | 1 |
Hypothyroidism, Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, CISPLATIN, CISPLATIN, |
||||
| 46 | 26542901 |
US |
2 | |
Disease progression, |
||||
EDARAVONE, EDARAVONE, |
||||
| 47 | 26543218 |
CN |
70 | 2 |
Acute respiratory failure, Adenocarcinoma gastric, Disease progression, Myelosuppression, Leukopenia, Thrombocytopenia, Aspergillus infection, Influenza, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, DOXORUBICIN, PREDNISONE, |
||||
| 48 | 26543519 |
RU |
41 | 1 |
Disease progression, Pyoderma, |
||||
OBINUTUZUMAB, BENDAMUSTINE HCL, |
||||
| 49 | 26543621 |
US |
75 | 2 |
Myasthenic syndrome, Disease progression, Bacterial infection, Exposed bone in jaw, Sneezing, Choking, Dry mouth, Peripheral coldness, |
||||
AMIFAMPRIDINE PHOSPHATE, AMIFAMPRIDINE PHOSPHATE, ACYCLOVIR, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, BENZONATATE, DARATUMUMAB, ESTRADIOL, FAMOTIDINE, MAGNESIUM OXIDE, PYRIDOSTIGMINE BROMIDE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, DENOSUMAB, DENOSUMAB, VITAMIN E, |
||||
| 50 | 26543705 |
VN |
33 | 1 |
Disease progression, Therapy non-responder, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, |
||||
| 51 | 26543711 |
CN |
70 | 2 |
Acute respiratory failure, Adenocarcinoma gastric, Disease progression, Myelosuppression, Leukopenia, Thrombocytopenia, Aspergillus infection, Influenza, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, DOXORUBICIN, PREDNISONE, |
||||
| 52 | 26543800 |
VN |
69 | 1 |
Disease progression, Therapy non-responder, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, |
||||
| 53 | 26543906 |
44 | 1 | |
Hyperbilirubinaemia, Liver function test increased, Disease progression, Hospice care, |
||||
FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, CETUXIMAB, LEUCOVORIN CALCIUM, |
||||
| 54 | 26544043 |
IR |
63 | 2 |
Stevens-Johnson syndrome, Acute kidney injury, Systolic dysfunction, Sepsis, Disease progression, |
||||
CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, METHYLPREDNISOLONE, |
||||
| 55 | 26544068 |
US |
22 | 2 |
Disease progression, |
||||
PREDNISONE, CYCLOSPORINE, |
||||
| 56 | 26544073 |
EU |
75 | 1 |
Disease progression, |
||||
DOXORUBICIN, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 57 | 26544081 |
JP |
49 | 1 |
Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 58 | 26544304 |
EU |
69 | 2 |
Hepatotoxicity, Autoimmune hepatitis, Disease progression, Diarrhoea, |
||||
ATEZOLIZUMAB, CISPLATIN, ETOPOSIDE, |
||||
| 59 | 26544345 |
US |
1 | |
Injection site erythema, Disease progression, |
||||
OCRELIZUMAB AND HYALURONIDASE, OCRELIZUMAB, |
||||
| 60 | 26544787 |
CN |
68 | 1 |
Parkinsonism, Gastrooesophageal reflux disease, Hepatic mass, Chest discomfort, Disease progression, Nausea, Vomiting, Metastases to central nervous system, Lung neoplasm, Liver injury, Biliary obstruction, Malnutrition, COVID-19, Oxygen saturation decreased, Death, Dyspnoea, Cholelithiasis, Weight decreased, Pancreatic disorder, Cholestasis, |
||||
BEVACIZUMAB, |
||||
| 61 | 26545035 |
CN |
||
Disease progression, |
||||
POLATUZUMAB VEDOTIN, |
||||
| 62 | 26552020 |
2 | ||
Disease progression, |
||||
PIRTOBRUTINIB, |
||||
| 63 | 26535984 |
RU |
||
Disease progression, |
||||
PREDNISONE, CYTARABINE, |
||||
| 64 | 26536107 |
CN |
65 | 2 |
Myelosuppression, Disease progression, Hypothyroidism, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CISPLATIN, CISPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, CAPECITABINE, CAPECITABINE, CAPECITABINE, CAPECITABINE, |
||||
| 65 | 26536605 |
EU |
79 | 2 |
Disease progression, Neutropenia, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, BISOPROLOL FUMARATE, AMLODIPINE, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, MEROPENEM, RAMIPRIL, AMIKACIN, ACYCLOVIR, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, |
||||
| 66 | 26536624 |
EU |
2 | |
Disease progression, |
||||
BELANTAMAB MAFODOTIN, BORTEZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 67 | 26536879 |
EU |
72 | 1 |
Lymphoma, Disease progression, T-cell prolymphocytic leukaemia, Product use in unapproved indication, |
||||
ALEMTUZUMAB, |
||||
| 68 | 26536904 |
US |
2 | |
Disease progression, Product dose omission issue, |
||||
SONIDEGIB, |
||||
| 69 | 26536912 |
GB |
54 | |
Disease progression, |
||||
TEMOZOLOMIDE, |
||||
| 70 | 26537170 |
US |
1 | |
Disease progression, |
||||
EDARAVONE, EDARAVONE, |
||||
| 71 | 26537546 |
BR |
13 | 1 |
Disease progression, |
||||
TEMOZOLOMIDE, |
||||
| 72 | 26537556 |
US |
26 | 1 |
Disease progression, |
||||
PREDNISONE, METHYLPREDNISOLONE, SILTUXIMAB, |
||||
| 73 | 26537819 |
BR |
8 | 1 |
Disease progression, |
||||
TEMOZOLOMIDE, |
||||
| 74 | 26538496 |
EU |
1 | |
Disease progression, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 75 | 26538596 |
CN |
||
Disease progression, |
||||
PREDNISONE, INOTUZUMAB OZOGAMICIN, |
||||
| 76 | 26538993 |
US |
47 | 2 |
Disease progression, |
||||
OLAPARIB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 77 | 26539735 |
PY |
2 | |
Disease progression, |
||||
VEMURAFENIB, COBIMETINIB, |
||||
| 78 | 26539909 |
TR |
51 | 1 |
Disease progression, |
||||
ELOSULFASE ALFA, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 79 | 26540013 |
CN |
22 | 1 |
Progressive multifocal leukoencephalopathy, Disease progression, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, RITUXIMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 80 | 26540356 |
JP |
||
Cardiac failure, Disease progression, |
||||
| 81 | 26540704 |
RU |
1 | |
Disease progression, Cytokine release syndrome, |
||||
POLATUZUMAB VEDOTIN, VENETOCLAX, GLOFITAMAB, IBRUTINIB, LENALIDOMIDE, |
||||
| 82 | 26541306 |
US |
2 | |
Disease progression, Off label use, |
||||
GALSULFASE, |
||||
| 83 | 26543745 |
44 | 2 | |
Disease progression, |
||||
PALBOCICLIB, |
||||
| 84 | 26543908 |
68 | 2 | |
Breast cancer, Disease progression, |
||||
PALBOCICLIB, |
||||
| 85 | 26531197 |
EU |
73 | 1 |
General physical health deterioration, Disease progression, |
||||
| 86 | 26531788 |
US |
2 | |
Disease progression, Atrial fibrillation, Ventricular extrasystoles, Tendonitis, Mobility decreased, Stomatitis, Rash, Skin wrinkling, Epistaxis, Obstructive airways disorder, Increased tendency to bruise, Contusion, Fall, Joint injury, Affect lability, |
||||
ZANUBRUTINIB, ZANUBRUTINIB, |
||||
| 87 | 26531801 |
CN |
||
Disease progression, |
||||
POLATUZUMAB VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, |
||||
| 88 | 26531813 |
EU |
2 | |
Disease progression, |
||||
MIRVETUXIMAB SORAVTANSINE, |
||||
| 89 | 26532057 |
IN |
2 | |
Neuropathy peripheral, Pulmonary oedema, Laryngeal dyskinesia, Disease progression, Drug ineffective, |
||||
| 90 | 26532059 |
EU |
2 | |
Disease progression, |
||||
MIRVETUXIMAB SORAVTANSINE, |
||||
| 91 | 26532303 |
EU |
45 | |
Disease progression, Erysipelas, |
||||
SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, |
||||
| 92 | 26532397 |
JP |
64 | 1 |
Chronic graft versus host disease, Disease progression, |
||||
BELUMOSUDIL, |
||||
| 93 | 26532472 |
US |
69 | 2 |
Disease progression, Off label use, |
||||
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, CEFEPIME HYDROCHLORIDE, CEFEPIME, CEFEPIME HYDROCHLORIDE, CEFEPIME, |
||||
| 94 | 26532809 |
EU |
||
Disease progression, Inappropriate schedule of product administration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 95 | 26533203 |
GB |
1 | |
Disease progression, |
||||
BENDAMUSTINE HCL, BENDAMUSTINE HCL, POLATUZUMAB VEDOTIN, RITUXIMAB, RITUXIMAB, |
||||
| 96 | 26533700 |
EU |
79 | 2 |
Disease progression, Bacteraemia, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, AMIKACIN, FILGRASTIM, ACYCLOVIR, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, RAMIPRIL, BISOPROLOL FUMARATE, AMLODIPINE, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, |
||||
| 97 | 26533788 |
1 | ||
Disease progression, |
||||
APALUTAMIDE, |
||||
| 98 | 26533869 |
VN |
59 | 2 |
Therapy non-responder, Disease progression, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, |
||||
| 99 | 26534270 |
ZA |
50 | |
Cardiotoxicity, Angina pectoris, Neuropathy peripheral, Respiratory disorder, Eye disorder, Disease progression, Photopsia, |
||||
CAPECITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, SACITUZUMAB GOVITECAN, VINORELBINE, |
||||
| 100 | 26534290 |
AR |
64 | 2 |
Disease progression, Hypertension, Nausea, Vomiting, |
||||
CAPECITABINE, ADO-TRASTUZUMAB EMTANSINE, TRASTUZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28